Nucleic acid aptamers are often referred to as chemical antibodies. Because they possess several advantages, like their smaller size, temperature stability, ease of chemical modification, lack of immunogenicity and toxicity, and lower cost of production, aptamers are promising tools for clinical applications. Aptamers against cell surface protein biomarkers are of particular interest for cancer diagnosis and targeted therapy. In this study, we identified and characterized RNA aptamers targeting cells expressing integrin α5β1. This αβ heterodimeric cell surface receptor is implicated in tumor angiogenesis and solid tumor aggressiveness. In glioblastoma, integrin α5β1 expression is associated with an aggressive phenotype and a decrease in patient survival. We used a complex and original hybrid SELEX (selective evolution of ligands by exponential enrichment) strategy combining protein-SELEX cycles on the recombinant α5β1 protein, surrounded by cell-SELEX cycles using two different cell lines. We identified aptamer H02, able to differentiate, in cyto- and histofluorescence assays, glioblastoma cell lines, and tissues from patient-derived tumor xenografts according to their α5 expression levels. Aptamer H02 is therefore an interesting tool for glioblastoma tumor characterization.

INTRODUCTION
Glioblastoma (GBM), the highest-grade glioma tumor (grade IV), is the most aggressive and the most common malignant form of astrocytoma. Standard therapy consists of surgical resection to an extent that is safely feasible, followed by radiotherapy and concomitant chemotherapy with temozolomide (Stupp protocol).1 Despite these therapies, patients with GBM rarely live longer than 2 years.2 Histological features that characterize GBM are the presence of necrosis and abnormal growth of blood vessels around the tumor. Defining molecular profiles aims to develop molecularly guided approaches for the treatment of patients. The 2016 World Health Organization (WHO) classification scheme3 integrated phenotypic and genotypic parameters for CNS tumor classification. GBMs are divided into isocitrate dehydrogenase (IDH) 1 wild-type (about 90% of cases; corresponds to the most frequent primary or de novo GBM) and IDH-mutant GBM (about 10% of cases; corresponds to secondary GBM). Some of the GBM biomarkers that have been and are being discovered4 are cell surface protein biomarkers.5–8 Expression of cell surface protein is often remodeled in cancers. Genetic and epigenetic features altered in cancer9 include modification of copy number (under- or overexpression), truncations, mutations, and post-translational modifications. These modified proteins are major clinical targets for diagnosis and therapies, considering their accessibility for pharmacological compounds.

Tumor-specific tools such as aptamers can be used as recognition ligands to discriminate a tumor cell from another cell, as agonists or antagonists, or as carriers to deliver therapeutic payloads to targeted tumor cells.9–13 Aptamers are single-stranded DNA or RNA molecules that constitute an alternative class of molecules emerging as cancer-specific therapeutic, diagnostic, and theranostic tools.19–21 They are selected through an in vitro selection process, published for the first time in 1990 by three independent research groups,21 known as SELEX (selective evolution of ligands by exponential enrichment).22 Aptamers17 from the Latin aptère (to fit) and from the ancient Greek μερος (part) are often referred to as chemical antibodies15 because they bind to their specific targets with high affinity and specificity. Aptamers possess numerous advantages over antibodies, like smaller size, temperature stability, self-refolding, fewer side effects for immunotherapy, lack of immunogenicity and toxicity, more efficient penetration into biological compartments, chemical synthesis with high batch fidelity, and the option of site-specific and flexible introduction of linkers, reporters, functional groups,

1CNRS, UMR 7242, Biotechnologie et Signalisation Cellulaire, Institut de Recherche de l’Ecole de Biotechnologie de Strasbourg, Université de Strasbourg, 67400 Illkirch-Graffenstaden, France; 2CNRS, UMR 7021, Laboratoire de Bioimagerie et Pathologies, Tumoral Signaling and Therapeutic Targets, Faculté de Pharmacie, Université de Strasbourg, 67401 Illkirch, France; 3Département de Pharmacie, Centre de Lutte Contre le Cancer Paul Strauss, 67000 Strasbourg, France; 4EA 3430, Progression Tumorale et Micro-environnement, Approches Translationnelles et Épidémiologie, Université de Strasbourg, 67000 Strasbourg, France; 5CNRS, UMR 7199, Laboratoire de Conception et Application de Molécules Bioactives, Faculté de Pharmacie, Université de Strasbourg, 67401 Illkirch, France

Pierre Fechter,1,6 Elisabete Cruz Da Silva,2,6 Marie-Cécile Mercier,2 Fanny Noulet,2 Nelly Etienne-Seloum,2,3 Dominique Guenot,4 Maxime Lehmann,2 Romain Vauchelles,2 Sophie Martin,2 Isabelle Lelong-Rebel,2 Anne-Marie Ray,2 Cendrine Seguin,5 Monique Dontenwill,2 and Laurence Choulier2

Received 17 July 2018; accepted 3 May 2019; https://doi.org/10.1016/j.omtn.2019.05.006.
These authors contributed equally to this work
Correspondence: L. Choulier, CNRS, UMR 7021, Laboratoire de Bioimagerie et Pathologies, Tumoral Signaling and Therapeutic Targets, Faculté de Pharmacie, Université de Strasbourg, 67401 Illkirch, France.
E-mail: laurence.choulier@unistra.fr

This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
small interfering RNA (siRNA), nanoparticles, drugs, and so forth.\textsuperscript{10,11,14} Aptamers toward a wide variety of targets have been identified, the most common ones remaining proteins. We recently reviewed aptamers to more than 30 different tumor cell surface protein biomarkers,\textsuperscript{72} a few of them being heterodimeric receptors, such as tyrosine kinase receptors and cell adhesion molecules. However, selection of aptamers to cell surface proteins remains a complex process.

Among cell surface biomarkers, integrins are heterodimeric cell surface receptors for cell migration, differentiation, and survival.\textsuperscript{23} composed of $\alpha$ and $\beta$ subunits; their deregulation leads to cancer progression and therapy resistance.\textsuperscript{24} In mammals, 24 distinct integrins are formed by the combination of 18 $\alpha$ and 8 $\beta$ subunits. Specific heterodimers preferentially bind to distinct extracellular matrix proteins. Integrin $\alpha_5\beta_1$, the fibronectin receptor, belongs to the arginine, glycine, and aspartate (RGD) -binding integrin family. Overexpressed on tumor neovessels and on solid tumors, integrin $\alpha_5\beta_1$ is implicated in tumor angiogenesis and solid tumor aggressiveness. We and others have shown that $\alpha_5\beta_1$ integrin is a pertinent therapeutic target for GBM through its active role in tumor proliferation, migration, invasion, and resistance to chemotherapy.\textsuperscript{26–30} At the mRNA level, high $\alpha_5\beta_1$ integrin expression is associated with more aggressive tumors in patients with glioma.\textsuperscript{26} At the protein level, to date, only a few in situ analyses of GBM tumor section have been described.\textsuperscript{31,32} Further investigation of $\alpha_5\beta_1$ expression in GBM tumor cells as a potential prognostic factor and/or biomarker for diagnosis requires rapid and accurate tools.

In our study, aptamers to integrin $\alpha_5\beta_1$-expressing cells were selected by an original and complex hybrid SELEX process. This SELEX combines three rounds of protein-SELEX surrounded by 15 rounds of cell-SELEX on two different cell lines genetically modified to overexpress integrin $\alpha_5$, the human GBM U87MG cell line, and the Chinese hamster ovaries CHO-B2 cell line. Counterselection steps were performed on isogenic cell lines underexpressing $\alpha_5\beta_1$. For positive selection, CHO-B2 cells were manipulated to generate positive $\alpha_5$ cells by overexpressing human ITGA5. During the course of the SELEX process, the stringency was progressively increased by decreasing and increasing the incubation time for positive and counterselection, respectively by introducing competitor yeast tRNAs and increasing the number of washes (Table S1). Enrichment of RNA pools during selection was followed by qRT-PCR. The RNA pool at round 18 showed significant amplification compared with pools of preceding rounds (Figure S1) and was cloned. Of 82 sequenced molecules, five aptamers, named H02, H03, G10, B03, and G11, were selected for further characterization.

Identification of Aptamers Binding to $\alpha_5$-Expressing Cells
Aptamer H02 was the most frequently represented over all sequences (6 times over 82 sequences, 7.3%). Aptamers H03, G10, and G11 represented 3.7% of all sequenced molecules and aptamer B03 1.2%. The predicted secondary structures of the five aptamers (H02, G11, B03, G10, and H03) are shown in Figure 2A. Fixed regions (shown in dark red in Figure 2A) were designed to display partial complementarity and pre-organize aptamers in hairpin structures.\textsuperscript{35} The secondary structure predictions of aptamers H02, G11, and B03 are highly similar and very different from those of G10 and H03.

Identification of $\alpha_5\beta_1$-binding aptamers was performed using confocal fluorescence microscopy by incubating cyanine-5 (Cy5)-labeled aptamers at 4°C with the cells used for the cell-SELEX process. None of the five aptamers binds to U87MG $\alpha_5$ and CHO-B2 cells used for the counterselection steps (Figures S2A and S2B). Only aptamer H02 binds to the U87MG $\alpha_5$+ and CHO-B2 $\alpha_5$+ cells used for positive selection steps (Figures 2B and 2C). We next checked
whether, under the same methodological conditions, these aptamers were able to bind to U87MG cells at 37°C, the temperature used for the cell-SELEX process. H02, G11, B03, G10, and B03 did not bind to U87MG cells (Figure 3A). On U87MGα5+ cells, we observed strong binding not only of aptamer H02 but also, to a lesser extent, of aptamer G11 (Figure 3B). Because of its binding to U87MGα5+ cells at 4°C and at 37°C, subsequent analyses were performed using aptamer H02.

Validation of Integrin α5β1 as the Target of Aptamer H02

The SELEX process was performed to guide the selection toward integrin α5β1. However, cell-SELEX-based strategies have already led to the selection of aptamers against “undesirable targets,” meaning other proteins than the expected pre-identified targets.36,37

To validate integrin α5β1 as the target of our SELEX process, surface plasmon resonance (SPR) experiments were performed on a Biacore T200 instrument. Figure 4A shows the experimental scheme. Aptamer H02, with 2′-fluoro pyrimidines to increase its stability in SPR experiments, was captured on a CAP sensor chip via a biotin at its 5′ extremity. The aptamer was captured on a biotin CAPture reagent. Integrins were injected at concentrations ranging from 8–130 nM. We tested human integrins α5β1 and αvβ3 to check the H02 aptamer’s specificity. The surface was then
Figure 2. Aptamers Predicted Secondary Structures and Binding to α5-Expressing Cells

(A) Predicted secondary structure of aptamers H02, G11, B03, G10, and H03. Structures were predicted using the mfold web server. Nucleotides 1–19 and 50–68 correspond to fixed flanks of the candidate sequences. They are shown in dark red. ΔG values are noted above the structures. (B and C) Monitoring of the binding of five Cy5-labeled aptamers (H02, G11, B03, G10, and H03) at 5 μM on CHO-B2 and U87MG cell lines at 4°C using confocal microscopy. Nuclei, counterstained with Hoechst, are shown in royal blue. Aptamers, coupled to Cy5, are shown in white. (B) Binding on CHO-B2 α5+. α5 integrin is visualized, using the GFP-fused protein, in green. (C) Binding on U87MG α5+. α5 integrin was labeled with the IIA1 antibody and is shown in green. Images were captured at the same setting to allow direct comparison of staining patterns.
cap regeneration. CAP chips are designed to capture biotinylated molecules reversibly on the sensor surface, facilitating its regeneration. An SPR cycle thus consisted of injections of biotin CAPture reagent, biotinylated aptamer, integrin, and regeneration solution. Successive cycles were repeated, changing the integrin nature and concentration at each cycle (Figure S3A). Because of 2'-fluoro modifications, aptamer H02 was resistant to degradation over time, and aptamer injections were highly reproducible. The biotinylated aptamer reached the same level at each cycle with as low as 2% variation in responses over 20 cycles (Figure S3A). Therefore, the surface has the same properties during all experiments.

Figures 4B and 4C show the sensorgrams obtained for integrins α5β1 and αvβ3, respectively, after double referencing (subtraction of reference channel and buffer injection). The sensorgrams show that, even when responses are low, aptamer H02 bound specifically to integrin α5β1 in a dose-dependent manner but failed to interact with integrin αvβ3. The equilibrium affinity parameter (K_D) of the interaction between integrin α5β1 and aptamer H02 was 72 ± 11 nM. To ensure that integrin was active, positive controls were used. Figure S3B shows binding by SPR of integrin α5β1 to its natural ligand, fibronectin. We also demonstrated that only aptamer H02 was an α5β1 binder (but not, for example, aptamer B03; Figure S3C).

**H02 Aptamer Stability, Specificity and Affinity for U87MG α5+ Cells**

Because aptamer H02 is a non-modified RNA molecule, we tested its stability in the presence of cells at 4°C and 37°C in the buffer used for selection. The results (Figure S4A) confirmed that incubation on cells for 1 h, which corresponds to the maximum contact time of RNAs with cells during different assays, does not induce aptamer H02 degradation. However, this aptamer is extremely rapidly degraded when incubated on cells in a culture medium supplemented with 10% fetal bovine serum (FBS) (Figure S4A). If this aptamer had to be used under more complex conditions than in a simple buffer, then it would have to be modified to increase its nuclease sensitivity. For example the 2'-fluoro-modified H02 aptamer is very stable in contact with cells at 4°C and at 37°C as it is not degraded in the selection buffer and in a complex medium for at least 1 h (Figure S4B).
the two Cy5-labeled H02 and B03 aptamers, a shift was detected for CHO-B2 α5+ cells with aptamer H02 but not with aptamer B03. Figure S5 also confirmed that aptamer H02 was our best hit from SELEX because it binds much better to α5-expressing cells than aptamer G11.

The equilibrium affinity parameter $K_D$ of the interaction between aptamer H02 and U87MG α5+ cells was determined using flow cytometry (Figure 5B). Binding events associated with the fluorescence signal of different concentrations of aptamer, ranging from 0.15–5 μM, to a constant number of cells were measured. A $K_D$ of 277.8 ± 51.8 nM was determined by plotting the mean fluorescence of U87MG α5+ cells against the concentration of the H02 aptamer.

**H02 Aptamer Localization in U87MG α5+ Cells**

The localization of aptamer H02 on GBM U87MG α5+ cells was analyzed by confocal microscopy at 4°C and 37°C. Cells were incubated with the Cy5-labeled aptamer H02 and with the anti-α5 IIA1 antibody, followed by incubation of a secondary antibody labeled with Alexa 546. Spots of co-localization were detected between Alexa 546 and Cy5, which reflect spatial proximity between the α5 subunit and the aptamer H02, at 4°C and, to a lesser extent, at 37°C (Figures 6A and 6B). Aptamer H02 detected α5β1 mostly at the plasma membrane and at cell-cell junctions at 4°C, whereas punctuate labeling suggested internalized molecules at 37°C. The weaker co-localization observed with anti-β1 antibody and aptamer H02 (Figure 3B) is explained as the β1 subunit associates with different α subunits to form different integrins, whereas the α5 subunit associates only with the β1 subunit to form the fibronectin receptor.

We next wanted to confirm the internalization of aptamer H02 in α5-expressing cells at 37°C. To this end, adherent U87MG α5+ cells were labeled for 30 min with the Cy5-coupled aptamer H02 at five different concentrations (5, 2.5, 1.25, 0.6, and 0.3 μM). After cell fixation, cells were immunolabeled with the anti-EEA1 antibody to detect early endosomes and then analyzed by confocal microscopy. Figure 6C shows clear co-localization of aptamer H02 at 5, 2.5, and 1.25 μM with the anti-EEA1 antibody in U87MG α5+ cytoplasm, suggesting aptamer H02 endocytosis. A 3D reconstruction of whole z stacks is shown in Video S1.

Fluorescently labeled aptamers were not detected at lower concentrations (0.6 and 0.3 μM). The lower concentration limit of 1.25 μM corresponds to 4.5-fold the $K_D$ of the H02-cell interaction and, theoretically, to 82% receptor occupancy, governed by concentration and affinity. At 4°C, aptamers were not detected at concentrations lower than 5 μM (Figure S6), suggesting a different binding mechanism at 4°C and at 37°C. Figures 5A and 5S show that, in flow cytometry experiments, a difference could be detected at 4°C between H02 and aptamers B03 and G11 at concentrations lower than 1 μM. This difference may be due to the differences inherent to the two different techniques (flow cytometry versus confocal microscopy).
Aptamer molecules have the potential to revolutionize the field of diagnostics for the detection of cell-specific biomarkers. We evaluated the capacity of aptamer H02 to be a new tool for the characterization of GBM α5-expressing cells and tissues. We first characterized the ability of aptamer H02 to distinguish between 10 human GBM cell lines expressing different levels of the α5 subunit (Figure 7A). Among those are U87MG α5+ and U87MG α5−, used for cell-SELEX, and eight GBM cell lines, LN319, LN229, SF763, LN18, LNZ308, U373, T98G, and LN443. For aptacytchemical assays, confluent adherent cells were stained with the Cy5-labeled aptamer H02 at 4°C at 5 μM for 30 min. After cell fixation with paraformaldehyde, cells were immunolabeled with an anti-α5 primary antibody and a secondary antibody labeled with Alexa 546. Quantification of apta- and immunofluorescence of the different cell lines is shown in Figure 7B. A correlation coefficient of 0.78 has been determined between apta- and immunofluorescence. Integrin α5β1 expression in GBM cell lines can therefore be monitored in cytology and immuno- and aphahistochemistry assays. For immunostaining, the indi-rect assay consisted of successive incubation of an anti-α5 antibody and a secondary fluorescent antibody. Immunohistochemical assays showed that the TC7 tumor presented a higher integrin α5 expression level than the TC22 tumor (Figures 7C and 7D, top panels), in accordance with the mRNA levels. Aphahistochemical assays were performed by incubation of tumor sections with the Cy5-labeled aptamers H02 and G11 at the lower concentration limit of 1 μM, as outlined in H02 Aptamer Localization in U87MG α5+ Cells (Figures 7C and 7D, bottom panels). With aptamer H02, the fluorescence intensity is 4-fold higher on TC7 than on TC22. Under the conditions used for these histochemical experiments, the TC7 versus TC22 discrimination capacity was better with aptamer H02 than with the anti-α5 antibody. Aptamer G11 was also able to discriminate between both tissue sections, but to a much lesser extent than aptamer H02 (difference of 1.6-fold).

Aptamer H02 is therefore an interesting and promising new tool to differentiate cells according to their α5 subunit expression levels in cyto- and histochemistry experiments.

DISCUSSION

Biomarkers are indicators used to establish a diagnosis and prognosis and predict susceptibility to targeted therapies. GBM is the most aggressive form of brain tumors in adults. Despite intensive treatments, the prognosis of GBM patients remains poor. There is an urgent need to incorporate known biomarkers into clinical trials and routine clinical practice, which may assist not only with patient selection but also with adjustment of the treatment schedule based on patient-specific biology. Because differential expression of cell surface proteins often occurs in tumor cells, and considering their accessibility to extracellular ligands, these proteins provide biomarkers of interest in oncology. The identification of molecular probes specific for cell surface protein biomarkers is of great importance. Because of their high affinity and specificity toward their targets, aptamers are attractive and promising tools, alternatives to antibodies for clinical applications. In this study, using a complex and highly stringent SELEX strategy, we showed that it was possible to select an RNA aptamer specific to a pre-identified heterodimeric
Figure 6. Confocal Microscopy Analysis of Aptamer H02 on U87MG α5+

(A) Confocal microscopy analysis with aptamer H02 at 5 μM and the anti-α5 antibody IIA1 on U87MG α5+ cells at 4°C and 37°C. The aptamer is labeled with Cy5 (white). Incubation of antibody IIA1 was followed by incubation with a secondary antibody labeled with Alexa 546 (green). Nuclei are stained with Hoechst (blue). (B) Top: enlargement of the merged image in (A) at 4°C. Bottom: magnified images acquired by zooming in on the indicated areas of the parental image. Scale bars are shown in the lower right corners of the images. (C) Co-localization of aptamer H02 and the endocytosis marker EEA1. Shown are confocal images of U87MG α5+ cells incubated at 37°C with the
cell surface protein embedded in its natural environment. Integrin α5β1 is a GBM cell surface biomarker.26 Aptamer H02 was able to differentiate between high and low expression of the α5 integrin on cells and tissues. This aptamer is suitable for tumor characterization.

Two main processes have been developed to select aptamers specific for pre-determined cell surface proteins: protein- and cell-based SELEX.22 In protein-based SELEX, a purified protein is used as target, usually full-length or truncated (generally recombinant ectodomains). The major issues with the protein-based SELEX process are that purification of membrane proteins is not easy and that purified proteins may not adopt the same conformational state as in their endogenous cellular environment. Some aptamers identified through protein-based SELEX failed to recognize their target when embedded in whole living cells.42,43 In cell-based SELEX, targets are cell surface proteins in their cellular environment. This process is much more complex than protein-based SELEX. Modification of cell lines is often required to guide the selection toward the desired target, like over- and/or underexpression of the protein target for positive- and/or counterselection, respectively. Cell-SELEX generally employs cells genetically modified to overexpress a defined cell surface target for positive selection and mock cells for counterselection or mock cells for positive selection and isogenic cells underexpressing the cell surface target for counterselection.22 Cancer cell lines have been used for the cell-based SELEX process,9,44 both for therapy and diagnostic purposes.

Only three integrins (β2, αvβ3, and α6β4) have so far been used as pre-identified targets for the SELEX processes. Blind et al.45 selected, by protein-SELEX, RNA aptamers targeting a 46-mer peptide corresponding to the complete cytoplasmic domain of the β2 subunit of integrin αLβ2. Cells infected with vaccinia viruses encoding β2-specific aptamers enabled high-level cytoplasmic expression of RNA aptamers. Intracellular integrin-binding aptamers reduced inducible cell adhesion to the intercellular adhesion molecule 1 (ICAM-1). To target integrin αvβ3, two different protein-based SELEX processes and a cell-based SELEX were used to identify 2′-fluoropyrimidine RNA aptamers. The 2′-fluoropyrimidine modification confers increased nuclease resistance to RNA molecules. Aptamer Apta-αvβ3, selected on αvβ3 purified by immunofinity chromatography, was able to bind αvβ3 integrin expressed on the surface of live cells and to impair endothelial cell growth and survival.46-47 To select aptamers specific to homodimer αv and β3, Gong et al.48 developed a strategy called multivalent aptamer isolation (MAI)-SELEX. Two distinct selection stages were employed, the first being a classical affinity selection on the purified full-length αvβ3 integrin. The second, for specificity, leads selection to β3 because integrin αIIbβ3 served as a protein decoy. Two aptamers specific for αv and β3 were identified with affinities in the low nanomolar range. Takahashi et al.49 applied a process they called isogenic cell (Icell)-SELEX to identify RNA aptamers targeting αv integrins (integrin alpha subunit [ITGAV]), in which isogenic HEK293 cell lines were manipulated for counterselection by microRNA-mediated silencing and for positive selection by overexpression of target proteins. Integrin α6β4 has recently been the target of hybrid SELEX,50,51 a combination of protein- and cell-based SELEX processes, for which five rounds of cell-SELEX on PC-3 cells were followed by 7 rounds of protein-based SELEX on a recombinant α6β4 protein.52 In this last study, despite introduction of counterselection on PC-3 β4 integrin (ITGB4) knockdown cells to deplete single-stranded DNA (ssDNA) aptamers specific for cell surface markers other than the β4 subunit, the cell-SELEX process alone was not sufficient to prevent enrichment of non-target-specific aptamers.

To allow discovery of highly selective but also conformation-dependant aptamers and to guide the selection toward α5β1 integrin, the complex SELEX strategy we adopted presents two originalities compared with other SELEX strategies toward cell surface biomarkers. In our study, a hybrid SELEX combining successive rounds of cell-SELEX, protein-SELEX, and then again cell-SELEX was performed. Usually, in hybrid SELEX, the first rounds of selection are performed by cell-SELEX, and then rounds of selection are performed on the same version of the target in its purified form by protein-based SELEX.50,52 A reverse hybrid SELEX combines protein-SELEX followed by cell-SELEX.51,53,54 Consequently, our strategy combines hybrid SELEX and reverse hybrid SELEX (Figure 1). The second originality is that two different cell lines were used compared with one in previous studies. These two cell lines were the human GBM U87MG and the hamster CHO-B2 cell lines. Both cell lines were genetically transformed to express high levels of the human α5 subunit for positive selection rounds. These two cell lines do not express the same level of the α5 subunit (Figure 1). The first rounds of selection were performed on the U87MG α5+ cells to guide the selection toward cells highly expressing the α5 subunit. The last rounds of cell-SELEX were performed on CHO-B2 α5+ cells, a cell line expressing α5 levels similar to α5 expression of the wild-type GBM cell line U373, to guide the selection to a more natural expression and, probably, a more natural conformation and environment of the target. For counterselection rounds, the ideal cell line was CHO-B2 because it does not express the α5 subunit at all. U87MG α5− cells were stably transfected to repress the human α5 gene by transfecting a pSM2 plasmid coding for a short hairpin RNA (shRNA) targeting the α5 mRNA.26 Despite the fact that U87MG α5− cells were probably not fully depleted in α5, we showed that the differential expression level of α5 between U87MG α5+ and U87MG α5− cells (not detected in western blots) was high enough to permit a differential binding pattern of aptamer H02 (Figure 3B). The keys to this successful complex SELEX are the
Figure 7. Aptafluorescence on GBM Cells and Tissues

(A–D) Aptafluorescence on GBM cells (A and B) and tissues (C and D). (A) Western blot analysis. One representative western blot of the GBM cell lines (U87MG α5+, U87MG α5−, LN319, LN229, SF763, LN18, LN229, U373, LN18, and T98G) used in this study is shown at the top. Histograms, at the bottom, show the quantification of α5 integrin expression normalized to GAPDH levels (mean ± SEM of 3 independent experiments). GAPDH was used as a loading control. (B) Immuno-quantification versus apta-quantification of confocal fluorescence experiments on ten GBM cell lines. Immuno-quantification was performed with an anti-α5 antibody, followed by a secondary antibody coupled to Alexa 546. Aptafluorescence was performed with the Cy5-labeled aptamer H02. Quantification of mean fluorescence intensity (a.u.) was performed on at least 5 randomly selected images per cell line. The correlation coefficient is 0.78, with p < 0.0001. (C) Immuno-fluorescence (top panel) and apta-fluorescence (bottom panel) of patient-derived tumor xenografts TC7 and TC22, showing high and low levels of α5 integrins, respectively. For immunofluorescence, detection of α5 (in white) was performed with an antibody, followed by a secondary antibody coupled to Alexa 647. For aptafluorescence, detection of α5 (in white) was performed with the Cy5-labeled aptamers H02 and G11. DAPI staining is shown in blue. Images were captured at the same setting to allow direct comparison of staining patterns. One representative image per condition is shown. (D) Quantification of immuno-fluorescence (top panel) and apta-fluorescence (bottom panel) by confocal microscopy. Histograms show quantification of 10 to 26 different images per condition. Statistical analyses were done with Student’s t test (***p < 0.0001 and **p < 0.003).
use of alternative rounds of cell- and protein-SELEX rounds, the use of at least two different cell lines to remove unspecific binding, and the high differential expression of the target expressed on cells used for positive selection compared with cells used for counterselection.

Aptamer H02 was selected after 18 rounds of a stringent SELEX process. This aptamer was the most represented sequence. It is not degraded in contact with cells under the conditions used for the experiments. As for aptamers G11 and B03, the predicted secondary structure of aptamer H02 is highly stable in imperfect hairpins. Using label-free SPR experiments, integrin α5β1 was validated as the target of aptamer H02 (Figure 4B). Aptamer H02 was also identified as a binder of α5-expressing cells on cells used for positive selection or on other GBM cells in aptacytometry assays (Figures 7A, and 7B). U87MG α5+ cells incubated with aptamer H02 allowed internalization of aptamer H02 at 37°C by endocytosis of the α5β1 cell surface receptor. A $K_D$ value of 277.8 ± 51.8 nM was determined for the interaction between aptamer H02 and U87MG α5+ cells. This affinity value is of the same order of magnitude than the 100–400 nM that have been determined for aptamers characterized toward other integrins by cell- or hybrid SELEX. By SPR, a $K_D$ of 72 nM was determined for the interaction between aptamer H02 and integrin α5β1. The 3.8-fold difference in binding affinity between the aptamer-recombinant protein and aptamer-cell interaction can certainly be explained by the different techniques used (flow cytometry versus SPR) and by conformational differences between cell surface proteins and soluble recombinant proteins. However, it is not due to the use of the H02-2'F aptamer in SPR versus the non-modified aptamer in flow cytometry because the H02-2'F and non-modified H02 aptamers have the same affinity for U87MG α5+ cells (data not shown). Only a few studies compared aptamer binding with isolated proteins and with tumor cell surface protein biomarkers. The 5-fold difference, which is of the same order of magnitude than the difference observed in our study, has been described for the OX40-aptamer interaction and can be explained by conformational differences.

In the field of precision oncology, histological detection of specific biomarkers is a crucial diagnostic tool. Immunohistochemistry is a cheap, easy method for detection of tumor biomarkers. Aptahistochemistry is a new option, still rarely described, for which aptamers, as a new class of probes, are used instead of antibodies. In our study, we used aptamer H02 directly end-labeled with a single cyanine 5 fluorescent dye. Aptamer H02 was able to specifically interact with α5-overexpressing tumor tissues from patient-derived xenografts (Figures 7C and 7D) because it efficiently differentiates TC7 (tissue with high α5 expression) from TC22 (tissue with low α5 expression). Aptamer H02 is an effective molecular probe for labeling histological tissue sections and detection of the α5β1 biomarker on tumor cells. Aptamer probes may become powerful tools for pathologists to characterize tumor tissues because the protocols are simple to implement, straightforward to automate, and can be applied to paraffin-embedded cancer tissue as well as to frozen tumor tissues. Aptahistochemistry could certainly be easily extrapolated to biomarker multiplexing detection to assess co-localization of different markers on the same tumor section. Aptamer H02 targeting integrin α5β1 as well as other aptamers targeting other GBM biomarkers might therefore help to better characterize GBM inter-tumoral as well as intra-tumoral heterogeneity, which would have implications for personalized targeted therapies. A recent review describes the technicalities of the current applications of aptahistochemistry. Aptaffluorescence will probably reduce the cost, time, and cross-reactivity concerns compared with indirect immunofluorescence approaches generally based on primary and then secondary antibodies. Conjugation of dye on aptamers is easy and reduces the risk of disrupting the aptamer structure compared with antibodies generally labeled with multiple tags. Compared with an antibody, the aptamer’s smaller size (10-fold reduction in size) allows better penetration in tissues, particularly in applications for which epitope accessibility is reduced, such as in fixed tissues. A further advantage of aptamers is that the target of interest is not limited to molecules that produce an immune response in the host animal, as for antibodies. Chemical synthesis of aptamers virtually eliminates the issue of batch-to-batch variation.

**Conclusion**

In conclusion, we characterized a new, original, and powerful aptamer tool to detect GBM tumoral cells and tissues expressing integrin α5β1. These detections might be extended for use in other cancers where α5β1 has proven to be a therapeutic target, such as colon cancer, ovarian cancer, breast cancer, lung tumors, and melanoma. For clinical translation, the structure of aptamer H02 will have to be confirmed, and aptamer H02 will be improved further by truncations to obtain the minimal active fraction and by increasing its resistance toward nucleases via modifications of its nucleic acid backbone and extremities. Internalized, an aptamer targeting integrin α5β1 might open roads for α5β1-specific therapeutic payload delivery. Endocytosis may be crucial for targeting and increasing the therapeutic efficacy of GBM drugs. Linked to a cytotoxic agent, an aptamer to integrin α5β1 could serve as a carrier for targeted therapeutic delivery. Such aptamers were very recently called “charomers.” Chemical synthesis of integrin α5β1 would be very powerful carriers to deliver therapeutic agents into targeted cells.

**MATERIALS AND METHODS**

**Materials**

The ssDNA library was synthetized and purified by Eurogentec (Seraing, Belgium). All RNA aptamers and chemicals were purchased from IBA and Sigma-Aldrich (Hamburg, Germany), respectively, unless otherwise stated. The sequences of all primers, the library, and aptamers from this study are described in Table S2.

**Cell Culture and Transfection**

Cell culture medium and reagents were from Lonza (Basel, Switzerland) or Gibco (Thermo Fisher Scientific, Waltham, MA, USA). U87MG cells were from the ATCC. U373MG and T98G cells were from ECACC (European Collection of Authenticated Cell Cultures, Sigma). LN319, LN229, LN443, LN18, and LN2308 cells were kindly provided by Prof. Monika Hegi (Lausanne, Switzerland), SF763 by Frédéric André (Marseille, France), and CHO-B2 by...
Wolfram Ruf (La Jolla, CA, USA). All GBM cells were routinely cultured in Eagle’s minimum essential medium (EMEM), 10% heat-inactivated FBS, and 2 mM glutamine. For U373MG and T98G, 1% non-essential amino acids and 1 mM sodium pyruvate were added to the medium. For CHO-B2 cells, EMEM was substituted for DMEM (high glucose). U87MG cells were stably transfected to over-express (U87MG α5+) and repress (U87MG α5−) the human α5 gene, as described previously. CHO-B2 cells lacked the α5 subunit. They were stably transfected by a pcDNA3.1 plasmid provided by Dr. Ruoshlati (La Jolla, CA, USA) to overexpress the human α5 integrin gene in fusion with the gene for GFP by using jetPRIME (Polyplus transfection) according to the manufacturer’s instructions and named CHO-B2 α5+ cells.

Expression and Purification of α5β1-Fc

The recombinant soluble human α5β1-Fc integrin (a gift from Martin Humphries, Manchester, UK) was produced from NSO culture supernatant and purified via the Fc domain on protein A-Sepharose as described previously. The purity of the protein was verified by Coomassie staining of SDS-polyacrylamide gels.

SELEX Strategy

The RNA library was obtained by transcription from a starting ssDNA library (Eurogentec) containing 30 random nucleotides (N30) and flanked by primer annealing sites: 5’-GTTGAGACTGACGGCTTCACTGC-3’. Two primers, P3’ (5’-GTTGAGACTGACGGCTTCACTGC-3’) and P5’ (5’-TAATACGACTCCTATAGTTAGTACGACGCTTCACTGC-3’), containing the T7 transcription promoter (underlined) were used for PCR amplification as described previously. The RNA pool was gel purified by denaturing (7 M urea) gel electrophoresis on an 8% polyacrylamide gel. The RNA was then purified by phenol-chloroform and ethanol precipitation. They were stably transfected by a pcDNA3.1 plasmid provided by Dr. Wolfram Ruf (La Jolla, CA, USA) to overexpress the human α5 integrin gene in fusion with the gene for GFP by using jetPRIME (Polyplus transfection) according to the manufacturer’s instructions and named CHO-B2 α5+ cells.

Flow Cytometry

Flow cytometry was performed with individual aptamers directly coupled to Cy5 at their 3’ end. For comparison of the binding profile of different aptamers to cells, aptamers were used at a final concentration of 500 nM. For determination of equilibrium binding affinities, aptamer H02 was used at concentrations of 0.15, 0.3, 0.6, 1.25, 2.5, and 5 μM. After detachment with EDTA (0.2 M), 300,000 cells were incubated for 30 min at 4°C with Cy5-labeled aptamers. As a control, cells were incubated with a 1/100 dilution of an anti-α5 antibody (mouse anti-human CD49e, IIA1 antibody, BD Chemigen) for 30 min, followed by 30-min incubation with Alexa 647-conjugated affine pure goat anti-mouse IgG (Jackson ImmunoResearch) at 10 μg/mL. After washing, cells were analyzed using a FACScalibur flow cytometer (Becton Dickinson), and the mean fluorescence intensity (counting 10,000 events) was measured using Flowing software 2.5.1. For KD determination, experiments were repeated three times, and data were evaluated using GraphPad Prism (version 5.04).

SPR Analyses of Aptamer H02-Integrin Interactions on a CAP Sensor Chip

All experiments were performed on a Biacore T200 instrument (GE Healthcare) at 25°C. The sensor surface and other Biacore consumables were purchased from GE Healthcare. Integrins α5β1 and αvβ3 were from R&D Systems. Running buffer was composed of PBS (10 mM), NaCl (150 mM), and MgCl₂ (1 mM), filtered through a 0.22-μm membrane, and supplemented with surfactant P20 (0.005% v/v). The biotin CAPture reagent, composed of streptavidin conjugated with an oligonucleotide, was stably hybridized to the complementary sequence of a CAP sensor chip following the biotin CAPture kit instructions (GE Healthcare). The biotinylated aptamer was denatured at 95°C for 3 min, incubated on ice, and then injected onto the biotin CAP reagent at 100 nM for 5 min at a flow rate of 30 μl/min.
10 μL/min. Five different concentrations of integrin (ranging from 8–130 nM) were injected into the flow cells at 10 or 30 μL/min for 300 s. Dissociation followed for 300 s. After each measurement, the sensor chip was washed with an injection of 6 M guanidine hydrochloride in 0.25 M NaOH as recommended by the manufacturer. The reference surface was treated similarly except that aptamer injection was omitted. Binding curves were double-reference-subtracted from the buffer blank and reference flow cell (without the aptamer). The equilibrium response was recorded 5 s before the end of integrin injection. The KD was determined by fitting the equilibrium response versus the [integrin] curve to a simple 1:1 interaction model with the Biacore T200 evaluation software (GE Healthcare).

**Western Blot**

Cells were lysed (1% Triton X-100, NaF [100 mmol/L], Na3PPIX [10 mmol/L], and Na2VO4 [1 mmol/L] in PBS, supplemented with complete anti-protease cocktail; Roche), and 10 μg of protein was separated by SDS-PAGE (Bio-Rad) and transferred to polyvinylidene fluoride (PVDF) membranes (Amersham). Blots were probed with antibodies to z5 integrin (H104, Santa Cruz Biotechnology) and to glyceraldehyde 3-phosphate dehydrogenase (GAPDH; Millipore). Horseradish peroxidase (HRP)-coupled secondary antibodies were from Promega. Proteins were visualized with enhanced chemiluminescence using the LAS4000 imager, and densitometry analysis was performed using the ImageJ software (GE Healthcare). GAPDH was used as housekeeping protein to serve as the loading control for cell lysate samples. Analyses were performed on three independent experiments.

**Fluorescence-Based Assays on Cell Lines**

The adherent CHO-B2 and GBM cell lines (U87MG z5+, U87MG z5−, LN319, LN229, LN443, SF763, LN18, LNZ308, U373, and T98G) were plated on sterile glass slides for one night at 37°C in culture medium, washed three times, and then saturated for 1 h at RT in selection buffer containing 2% BSA. Cy5-labeled aptamers were denatured at 95°C for 3 min and incubated on ice for 5 min before dilution in selection buffer to a 1 μM final concentration. Aptamers were incubated in tumor sections for 1 h at RT in a humid chamber, washed in selection buffer, dried, fixed in 4% PFA, and then washed three times in PBS. For immunofluorescence, slides were rinsed for 5 min in PBS-T (0.1% Tween 20 in PBS), dried, and then incubated in blocking buffer (2% BSA in PBS-T) for 1 h at RT in a humid chamber. Overnight incubation with anti-integrin z5 mAb 1928 (6B8516, Millipore, 1/200) in BB-1 (5% goat serum in PBS-T) at 1 h at RT in a humid chamber. Overnight incubation with anti-integrin z5 mAb 1928 (6B8516, Millipore, 1/200) in BB-1 was followed by a 5-min wash in PBS-T and by an incubation step with a 1/100 dilution of the goat anti-rabbit secondary antibody coupled to Alexa Fluor 647 (A21245, Life Technologies). Immunoo- and apta staining was followed by DAPI (10 μg/mL) staining for 30 min at RT to visualize cell nuclei. The stained samples were then washed in PBS, and coverslips were mounted onto tissue sections using fluorescent mounting medium (S3023, Dako).

**Fluorescence-Based Histochemical Assays of Patient-Derived Xenografts**

Two patient-derived heterotopic xenografts (PDXs) were selected for *in vivo* analysis. TC7 and TC22 GBM-PDXs presented high and low levels of z5 integrins, respectively. PDX mouse models were established using tissues surgically removed from patients as described previously. Integrin z5 was apta- and immunostained using formalin-fixed paraffin-embedded xenografts mounted on glass slides. Sections were deparaffinized, rehydrated, and subjected to an antigen unmasking protocol. Brieﬂy, sections were boiled at 100°C for 10 min in target retrieval solution (pH 9) (S2367, Dako), cooled down to RT for 20–40 min, and rinsed in H2O. For aptafluorescence, slides were rinsed for 5 min in selection buffer, dried, incubated in blocking buffer (2% BSA in selection buffer) for 1 h at RT, rinsed in H2O and then in selection buffer, and dried. RNA molecules were denatured at 95°C for 3 min and incubated on ice for 5 min before dilution in selection buffer to a 1 μM final concentration. Aptamers were incubated in tumor sections for 1 h at RT in a humid chamber, washed in selection buffer, dried, fixed in 4% PFA, and then washed three times in PBS. For immunofluorescence, slides were rinsed for 5 min in PBS-T (0.1% Tween 20 in PBS), dried, and then incubated in blocking buffer BB-1 (5% goat serum in PBS-T) for 1 h at RT in a humid chamber. Overnight incubation with anti-integrin z5 mAb 1928 (6B8516, Millipore, 1/200) in BB-1 was followed by a 5-min wash in PBS-T and by an incubation step with a 1/100 dilution of the goat anti-rabbit secondary antibody coupled to Alexa Fluor 647 (A21245, Life Technologies). Immunoo- and apta staining was followed by DAPI (10 μg/mL) staining for 30 min at RT to visualize cell nuclei. The stained samples were then washed in PBS, and coverslips were mounted onto tissue sections using fluorescent mounting medium (S3023, Dako).

**Confocal Imaging**

Images were acquired using a confocal microscope (Leica TCS SPE II, 63× magnification, oil immersion).

Mean fluorescence intensity on cells and tissues was measured using ImageJ software. Statistical analysis of data was performed with Student’s t test. Data were analyzed with GraphPad Prism version 5.04 and are represented as mean ± SEM.

**SUPPLEMENTAL INFORMATION**

Supplemental Information can be found online at [https://doi.org/10.1016/j.omtn.2019.05.006](https://doi.org/10.1016/j.omtn.2019.05.006).

**AUTHOR CONTRIBUTIONS**

Research was performed by P.F., A.-M.R. (aptamer identification), E.C.D.S. (apta- and immuno-fluorescence), and M.-C.M., F.N., C.S. (flow cytometry). D.G. and I.L.-R. provided useful reagents. P.F., E.C.D.S., M.D., and L.C. analyzed the data. P.F., M.L., R.V., N.E.-S., S.M., and M.D. provided expertise. L.C. designed, coordinated, and performed research and wrote the manuscript.
CONFLICTS OF INTEREST

The authors declare no competing interests.

ACKNOWLEDGMENTS

We thank Martin Humphries (Manchester, UK) for the gift of NSO cells expressing α5β1-Fc integrin and Julie Hémart and Antoine Schillinger for technical assistance. This work was supported by two contracts from the SATT Conectus Alsace (I14-057/01 and I18-020/01), a grant from the PEPS-IDEX program of the Université de Strasbourg (W15RPE24), the Ligue contre le cancer CCIR-Est (S19R417C), and the INTEGIO program of the Cancéropôle Grand-Est.

REFERENCES

1. Stuppy, R., Mason, W.P., van den Bent, M.J., Weller, M., Fisher, B., Taphoorn, M.J.B., Belanger, K., Brandes, A.A., Marosi, C., Bogdahn, U., et al.; European Organisation for Research and Treatment of Cancer Brain Tumor and Radiotherapy Groups; National Cancer Institute of Canada Clinical Trials Group (2005). Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N. Engl. J. Med. 352, 987–996.

2. Woodworth, G.F., Dunn, G.P., Nance, E.A., Hanes, J., and Brem, H. (2014). Emerging insights into barriers to effective brain tumor therapeutics. Front. Oncol. 4, 126.

3. Louis, D.N., Perry, A., Reifenberger, G., von Deimling, A., Figarella-Branger, D., Cavenee, W.K., Ohgaki, H., Wiestler, O.D., Kleihues, P., and Ellison, D.W. (2016). The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary. Acta Neuropathol. 131, 803–820.

4. Hug, A.L., Garzon-Muvdi, T., and Lim, M. (2017). Biomarkers and Immunotherapeutic Targets in Glioblastoma. World Neurosurg. 102, 494–506.

5. Cloughesy, T.F., Cavenee, W.K., and Mishel, P.S. (2014). Glioblastoma: from molecular pathology to targeted treatment. Annu. Rev. Pathol. 9, 1–25.

6. Wadajkar, A.S., Dancy, J.G., Hersh, D.S., Anastasiadis, P., Tran, N.L., Woodworth, G.F., Winkles, J.A., and Kim, A.J. (2017). Tumor-targeted nanotherapeutics: overcoming treatment barriers for glioblastoma. Wiley Interdiscip. Rev. Nanomed. Nanobiotechnol. Published online November 4, 2016. https://doi.org/10.1002/wnan.1439.

7. Jacci, N., Seboeck, R., Hofmann, E., and Eger, A. (2017). ErbB Family Signalling: A Paradigm for Oncogene Addiction and Personalized Oncology. Cancers (Basel) 9, 33.

8. Coe, A.P., Askari, J.A., Kline, A.D., Robinson, M.K., Kirby, H., Stephens, P.E., and Tschumper, J. (2018). Generation of a minimal α5β1 integrin antagonist, α5β1opath. Biochim. Biophys. Acta 1793, 354–367.

9. Freije, W.A., Castro-Vargas, F.E., Fang, Z., Horvath, S., Cloughesy, T., Liau, L.M., Mishel, P.S., and Nelson, S.F. (2004). Gene expression profiling of gliomas strongly predicts survival. Cancer Res. 64, 6503–6510.

10. Phillips, H.S., Kharbanda, S., Chen, R., Forrest, W.F., Soriano, R.H., Wu, T.D., Misra, A., Ngim, J.C., Colman, H., Souron, L., et al. (2006). Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis. Cancer Cell 9, 157–173.

11. Riemschneider, M.J., Mueller, W., Betensky, R.A., Mohapatra, G., and Louis, D.N. (2005). In situ analysis of integrin and growth factor receptor signaling pathways in human glioblastomas suggests overlapping relationships with focal adhesion kinase activation. Am. J. Pathol. 167, 1379–1387.

12. Cosset, E.C., Godel, J., Eintz Werlé, N., Guerin, E., Guenot, D., Froelich, S., Bonnet, D., Pinel, S., Plenat, F., Chastagner, P., et al. (2012). Involvement of the TGFβ pathway in the regulation of α5β1 integrin by caviolin-1 in human glioblastoma. Int. J. Cancer 131, 601–611.

13. Roche Gomes, S., Miguel, J., Azéma, L., Eimer, S., Ries, C., Dausse, E., Loiseau, H., Allard, M., and Toulmé, J.I. (2012). Caviolin-1 as a Pertinent Therapeutic Target in Solid Tumors. Cancers (Basel) 4, 33.

14. Mercier, M.-C., Donnten-will, M., and Choulier, L. (2017). Selection of Nucleic Acid Aptamers Targeting Tumor Cell-Surface Protein Biomarkers. Cancers (Basel) 9, E69.

15. Hynes, R.O. (2002). Integrins: bidirectional, allosteric signaling machines. Cell 110, 673–687.

16. Desrosediller, J.S., and Chersh, D.A. (2010). Integrins in cancer: biological implications and therapeutic opportunities. Nat. Rev. Cancer 10, 9–22.

17. Bouvier-Müller, A., and Ducongé, F. (2018). Application of aptamers for in vivo molecular imaging and theranostics. Adv. Drug Deliv. Rev. 134, 94–106.

18. Kim, M., Kim, D.M., Kim, K.S., Jung, W., and Kim, D.E. (2018). Applications of Cancer Cell-Specific Aptamers in Targeted Delivery of Anticancer Therapeutic Agents. Molecules 23, 830.

19. Ellington, A.D., and Szostak, J.W. (1990). In vitro selection of RNA molecules that bind specific ligands. Nature 346, 818–822.

20. Tuerk, C., and Gold, L. (1990). Systematic evolution of ligands by exponential enrichment: RNA ligands to bacteriophage T4 DNA polymerase. Science 249, 505–510.

21. Robertson, D.L., and Joyce, G.F. (1990). Selection in vitro of an RNA enzyme that specifically cleaves single-stranded DNA. Nature 344, 467–468.

22. Mestre, M.B. (2018). Aptamers as Diagnostic Tools in Cancer. Pharmaceuticals (Basel) 9, 220.

23. Bové, J.F. (2012). Aptamers: A new technological platform in cancer therapy. Wiley Interdiscip. Rev. Nanomed. Nanobiotechnol. 4, 90–104.

24. Kim, K., Jung, W., and Kim, D.E. (2018). Applications of Aptamers for Cancer Therapy. Cancers (Basel) 10, 818.

25. Ellington, A.D., and Szostak, J.W. (1990). In vitro selection of RNA molecules that bind specific ligands. Nature 346, 818–822.

26. Schreiner, C.L., Bauer, J.S., Danilov, Y.N., Hussein, S., Szczekan, M.M., and Juliano, R.L. (1989). Isolation and characterization of Chinese hamster ovary cell variants expressing Fc integrin and Julie Hémart and Antoine Schillinger for technical assistance. This work was supported by two contracts from the SATT Conectus Alsace (I14-057/01 and I18-020/01), a grant from the PEPS-IDEX program of the Université de Strasbourg (W15RPE24), the Ligue contre le cancer CCIR-Est (S19R417C), and the INTEGIO program of the Cancéropôle Grand-Est.

27. Maglott, A., Bartik, P., Cosgun, S., Klotz, F., Ronodi, P., Fuhrmann, G., Takeda, K., Martin, S., and Donnten-will, M. (2006). The small α5β1 integrin antagonist, α5β1opath, reduces proliferation and clonogenicity of human astrocytoma cells. Cancer Res. 66, 6002–6007.

28. Martin, S., Cosset, E.C., Terrand, J., Maglott, A., Takeda, K., and Donnten-will, M. (2009). Caviolin-1 regulates glioblastoma aggressiveness through the control of α5β1/Fc integrin expression and modulates glioblastoma responsiveness to ST749, an α5β1 integrin antagonist. Biochim. Biophys. Acta 1793, 354–367.

29. Freije, W.A., Castro-Vargas, F.E., Fang, Z., Horvath, S., Cloughesy, T., Liau, L.M., Mishel, P.S., and Nelson, S.F. (2004). Gene expression profiling of gliomas strongly predicts survival. Cancer Res. 64, 6503–6510.

30. Phillips, H.S., Kharbanda, S., Chen, R., Forrest, W.F., Soriano, R.H., Wu, T.D., Misra, A., Ngim, J.C., Colman, H., Souron, L., et al. (2006). Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis. Cancer Cell 9, 157–173.

31. Riemschneider, M.J., Mueller, W., Betensky, R.A., Mohapatra, G., and Louis, D.N. (2005). In situ analysis of integrin and growth factor receptor signaling pathways in human glioblastomas suggests overlapping relationships with focal adhesion kinase activation. Am. J. Pathol. 167, 1379–1387.

32. Cosset, E.C., Godel, J., Eintz Werlé, N., Guerin, E., Guenot, D., Froelich, S., Bonnet, D., Pinel, S., Plenat, F., Chastagner, P., et al. (2012). Involvement of the TGFβ pathway in the regulation of α5β1 integrin by caviolin-1 in human glioblastoma. Int. J. Cancer 131, 601–611.

33. Roe Gomes, S., Miguel, J., Azéma, L., Eimer, S., Ries, C., Dausse, E., Leiseau, H., Allard, M., and Toulmé, J.I. (2012). Caviolin-1 as a Pertinent Therapeutic Target in Solid Tumors. Cancers (Basel) 4, 33.
37. Xu, L., Zhang, Z., Zhao, Z., Liu, Q., Tan, W., and Fang, X. (2013). Cellular Internalization and Cytotoxicity of Aptamers Selected from Lung Cancer Cell. Am. J. Biomed. Sci. 5, 47–58.

38. Suenaga, E., Mizuno, H., and Pemetcha, K.K.R. (2012). Monitoring influenza hemagglutinin and glican interactions using surface plasmon resonance. Biosens. Bioelectron. 32, 195–201.

39. Basiji, D.A., Orlyn, W.E., Liang, L., Venkatasachalam, V., and Morrissey, P. (2007). Cellular image analysis and imaging by flow cytometry. Clin. Lab. Med. 27, 653–670, vii.

40. Bauer, M., Macdonald, J., Henri, J., Duan, W., and Shigdar, S. (2016). The Application of Aptamers for Immunohistochemistry. Nucleic Acid Ther. 26, 120–126.

41. Szopa, W., Burley, T.A., Kramer-Marek, G., and Kaspera, W. (2017). Diagnostic and Therapeutic Biomarkers in Glioblastoma: Current Status and Future Perspectives. BioMed Res. Int. 2017, B013575.

42. Liu, Y., Kuan, C.-T., Mi, J., Zhang, X., Clary, B.M., Bigner, D.D., and Sullenger, B.A. (2009). Aptamers selected against the unglycosylated EGFRVIII ectodomain and delivered intracellularly reduce membrane-bound EGFRVIII and induce apoptosis. Biochem. J. 390, 137–144.

43. Chauveau, F., Aissouni, Y., Hamm, J., Boutin, H., Libri, D., Ducongé, F., and Tavitian, B. (2007). Binding of an aptamer to the N-terminal fragment of VCAM-1. Bioorg. Med. Chem. Lett. 17, 6119–6122.

44. Ohuchi, S. (2012). Cell-SELEX Technology. BioRes. 1, 265–272, Open Access.

45. Blind, M., Kolanus, W., and Famulok, M. (1999). Cytoplasmic RNA modulators of an inside-out signal-transduction cascade. Proc. Natl. Acad. Sci. USA 96, 3606–3610.

46. Mi, J., Zhang, X., Giangrande, P.H., McNamara, J.O., Nimjee, S.M., Sarraf-Yazdi, S., Sullenger, B.A., and Clary, B.M. (2005). Targeted inhibition of alphavbeta3 integrin with an RNA aptamer impairs endothelial cell growth and survival. Biochem. Biophys. Res. Commun. 318, 956–963.

47. Rackman, J., Gold, L., Stephens, A., and Janjic, N. (2001). Nucleic acid ligands to integrins. US patent US6094535 B2, filed December 18, 2001, and granted August 22, 2006.

48. Gong, Q., Wang, J., Ahmad, K.M., Coordas, A.T., Zhou, J., Nie, J., Steward, R., Thomson, J.A., Rossi, J.J., and Soto, H.T. (2012). Selection strategy to generate aptamer pairs that bind to distinct sites on protein targets. Anal. Chem. 84, 5365–5371.

49. Takahashi, M., Sakota, E., and Nakamura, Y. (2016). The efficient cell-SELEX strategy, Icell-SELEX, using isogenic cell lines for selection and counter-selection to generate RNA aptamers to cell surface proteins. Biochimie 131, 77–84.

50. Poustie, C., Cerchia, L., Gombert, K., Aissouni, Y., Boulay, J., De Francisco, V., Libri, D., Tavitian, B., and Ducongé, F. (2006). Comparison of different strategies to select aptamers against a transmembrane protein target. Oligonucleotides 16, 323–335.

51. Zhu, G., Zhang, H., Jacobson, O., Wang, Z., Chen, H., Yang, X., Niu, G., and Chen, X. (2017). Combinatorial Screening of DNA Aptamers for Molecular Imaging of HER2 in Cancer. Bioconjug. Chem. 28, 1068–1075.

52. Berg, K., Lange, T., Mittelberger, F., Schumacher, U., and Hahn, U. (2016). Selection and Characterization of an 26 b Integrin blocking DNA Aptamer. Mol. Ther. Nucleic Acids 5, e294.

53. Wilner, S.E., Wengertner, R., Maier, K., de Lourdes Borba Magalhães, M., Del Amo, D.S., Pai, S., Opara, F., Rizzoli, S.O., Yan, A., and Levy, M. (2012). An RNA alternative to human transferrin: a new tool for targeting human cells. Mol. Ther. Nucleic Acids 1, e21.

54. Bolta, A., Piater, B., Teleskis, L., Gunther, R., Kolmar, H., and Hock, B. (2011). Bi-specific aptamers mediating tumor cell lysis. J. Biol. Chem. 286, 21896–21905.

55. Pratico, E.D., Sullenger, B.A., and Nair, S.K. (2013). Identification and characterization of an agonistic aptamer against the T cell costimulatory receptor, OX40. Nucleic Acid Ther. 23, 35–43.

56. Zaray, G.S., Ivanchenko, T.I., Vpanchenko, T.N., Grigorieva, V.L., Glazyrin, Y.E., Koloskovskaya, O.S., Garazha, I.V., Barinov, A.A., Krat, A.V., Mironov, G.G., et al. (2017). DNA Aptamers for the Characterization of Histological Structure of Lung Adenocarcinoma. Mol. Ther. Nucleic Acids 6, 150–162.

57. Pu, Y., Liu, Z., Lu, Y., Yuan, P., Liu, J., Yu, B., Wang, G., Yang, C.J., Liu, H., and Tan, W. (2015). Using DNA aptamer probe for immunostaining of cancer frozen tissues. Anal. Chem. 87, 1919–1924.

58. Zeng, Z., Zhang, P., Zhao, N., Sheehan, A.M., Tung, C.-H., Chang, C.-C., and Zu, Y. (2010). Using oligonucleotide aptamer probes for immunostaining of formalin-fixed and paraffin-embedded tissues. Mod. Pathol. 23, 1553–1558.

59. Blom, S., Paavolainen, L., Bychkov, D., Turkki, R., Mikki-Teeri, P., Hemmes, A., Välimäki, K., Lundin, J., Kallioniemi, O., and Pellinen, T. (2017). Systems pathology by multiplexed immunohistochemistry and whole slide digital image analysis. Sci. Rep. 7, 15580.

60. Bukari, B.A., Citrano, M., Ching, E.S., Bilbana, M.P., Rozhdestvensky, T., and Tang, T.-H. (2017). Aptahistochemistry in diagnostic pathology: technical scrutiny and feasibility. Histochim. Cell Biol. 147, 545–553.

61. Xiang, D., Zheng, C., Zhou, S.-F., Qiao, S., Tran, P.H.-L., Pu, C., Li, Y., Kong, L., Kouzani, A.Z., Lin, J., et al. (2015). Superior Performance of Aptamer in Tumor Penetration over Antibody: Implication of Aptamer-Based Theranostics in Solid Tumors. Theranostics 5, 1083–1097.

62. Sun, H., Tan, W., and Zu, Y. (2016). Aptamers: versatile molecular recognition probes for cancer detection. Analyst (Lond.) 141, 403–415.

63. Wang, T., Chen, C., Larcher, L.M., Barrero, R.A., and Veedu, R.N. (2019). Three decades of nucleic acid aptamer technologies: Lessons learned, progress and opportunities on aptamer development. Biotechnol. Adv. 37, 28–50.

64. Hahn, U. (2017). Charmonans-Interleukin-6 Receptor Specific Aptamers for Cellular Internalization and Targeted Drug Delivery. Int. J. Mol. Sci. 18, E2641.

65. Dousse, E., Cazeneve, C., Rayner, B., and Toûmè, J.-J. (2005). In vitro selection procedures for identifying DNA and RNA aptamers targeted to nucleic acids and proteins. Methods Mol. Biol. 288, 391–410.

66. Corpet, F. (1988). Multiple sequence alignment with hierarchical clustering. Nucleic Acids Res. 16, 1081–1089.

67. Zakeri, Z. (2003). Mfold web server for nucleic acid folding and hybridization prediction. Nucleic Acids Res. 31, 3406–3415.

68. Blandin, A.-F., Nolet, F., Renner, G., Mercier, M.-C., Choulter, I., Vauchelles, R., Ronde, P., Carreira, F., Etienne-Selloum, N., Vereb, G., et al. (2016). Glial cell dispersion is driven by α5 integrin-mediated cell matrix and cell-cell interactions. Cancer Lett. 376, 328–338.

69. Leurard, P., Taillandier, L., Medioni, J., Aguirre-Cruz, L., Grinière, E., Marie, Y., Kuja, M., Golmard, J.L., Duprez, A., Delattre, Y.J., et al. (2004). Distinct responses of xenografted gliomas to different alkylating agents are related to histology and genetic alterations. Cancer Res. 64, 4648–4653.

70. Pinel, S., Mriouah, J., Vandamme, M., Chateau, A., Plénat, F., Guérin, E., Taillandier, L., Bernier-Chastagner, V., Merlin, J.L., and Chastagner, P. (2013). Synergistic anti-tumor effect between gefitinib and fractionated irradiation in anaplastic oligodendrogliomas cannot be predicted by the Egfr signaling activity. PLoS ONE 8, e68333.